|
|
News Breaks | | | | January 17, 2013 | | 07:07 EDT |  | EBS | Emergent BioSolutions initiates Phase 2 clinical trial for anthrax vaccine
Emergent BioSolutions initiated a Phase 2 clinical trial for NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject. The Phase 2 clinical trial is designed to evaluate the safety and immunogenicity of NuThrax for post-exposure prophylaxis of anthrax infection using two and three dose immunization schedules and two dose levels. The study plans to enroll 168 healthy adult volunteers. Preliminary data from this study are expected in Q4. This Phase 2 clinical trial is being conducted with support from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health of HHS. | |
|
News For EBS From The Last 14 Days Check below for free stories on EBS the last two weeks. |
|
|
| May 10, 2013 | | 07:24 EDT |  | EBS | Credit Suisse to host a conference
 Subscribe for More Information | |
|
|
|
|
|
|
